NASDAQ:DNLI

Denali Therapeutics Q1 2025 Earnings Results & Report

Denali Therapeutics logo
$18.00 -0.08 (-0.44%)
Closing price 04:00 PM Eastern
Extended Trading
$18.00 0.00 (0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Denali Therapeutics missed analyst earnings expectations in its Q1 2025 results, released May 6, 2025. The company reported EPS of -$0.78 versus the -$0.71 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Denali Therapeutics EPS Results

Actual EPS
-$0.78
Consensus EPS
-$0.71
Beat/Miss
Missed by -$0.07
One Year Ago EPS
-$0.68
EPS Beat Rate
6 of last 8 quarters

Denali Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.24 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Denali Therapeutics Q1 2025 Earnings FAQ

Denali Therapeutics (NASDAQ:DNLI) reported earnings of -$0.78 per share for Q1 2025, missing the consensus estimate of -$0.71. The report was announced on Tuesday, May 6, 2025.

Denali Therapeutics Earnings Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
See More Denali Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Denali Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Denali Therapeutics and other key companies, straight to your email.

About Denali Therapeutics

Denali Therapeutics (NASDAQ:DNLI) is a biotechnology company focused on developing medicines for neurodegenerative diseases and other disorders involving the nervous system. Founded in 2015, the company is headquartered in South San Francisco, California.

Its research and development programs target conditions including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders. Denali’s portfolio includes investigational drug candidates that aim to address underlying disease processes, as well as its TransportVehicle platform, designed to help therapeutic molecules cross the blood-brain barrier.

Denali was co-founded by Ryan Watts, who serves as the company’s chief executive officer. Its medicines remain in development, and the company’s work includes research and clinical testing of potential treatments for patients with neurological conditions.

View Denali Therapeutics Profile